Teva Pharmaceuticals Reports the Results of Uzedy in P-III Trial as an Extended-Release Injectable Suspension for Schizophrenia
Shots:
- The P-III (RISE) study evaluates the safety & efficacy of Uzedy (SC inj.) vs PBO (n=181) on schizophrenia patients (n=544) randomly receiving the drug at qm (n=183) & q2m (n=180)
- The results depicted that the Uzedy significantly extended the time of impending relapse by 5 & 2.7 times leading to a reduction in risk of relapse by 80% & 62.5% vs PBO. Moreover, the drug showed clinically relevant plasma concentrations within 24hrs. which was maintained at varied dosage intervals
- The company published the results from the P-III (RISE) study in ‘The Lancet Psychiatry.’ The data from the trial suppored Uzedy ‘s US FDA approval earlier in April 2023 as an SC inj. for Schizophrenia
Ref: Teva | Image: Teva
Related Post:- Teva and MedinCell Receive the US FDA’s Approval of Uzedy (risperidone) Extended-Release Injectable Suspension for Schizophrenia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
